Logo image of BTAI

BIOXCEL THERAPEUTICS INC (BTAI) Stock Fundamental Analysis

NASDAQ:BTAI - Nasdaq - US09075P1057 - Common Stock - Currency: USD

2.13  -0.17 (-7.39%)

After market: 2.13 0 (0%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BTAI. BTAI was compared to 571 industry peers in the Biotechnology industry. BTAI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BTAI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BTAI has reported negative net income.
BTAI had a negative operating cash flow in the past year.
In the past 5 years BTAI always reported negative net income.
In the past 5 years BTAI always reported negative operating cash flow.
BTAI Yearly Net Income VS EBIT VS OCF VS FCFBTAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

BTAI has a Return On Assets of -145.21%. This is amonst the worse of the industry: BTAI underperforms 84.19% of its industry peers.
Industry RankSector Rank
ROA -145.21%
ROE N/A
ROIC N/A
ROA(3y)-122.7%
ROA(5y)-99.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTAI Yearly ROA, ROE, ROICBTAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600

1.3 Margins

BTAI has a Gross Margin of 10.98%. This is in the better half of the industry: BTAI outperforms 74.07% of its industry peers.
The Profit Margin and Operating Margin are not available for BTAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTAI Yearly Profit, Operating, Gross MarginsBTAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

1

2. Health

2.1 Basic Checks

BTAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BTAI has more shares outstanding
BTAI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, BTAI has a worse debt to assets ratio.
BTAI Yearly Shares OutstandingBTAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
BTAI Yearly Total Debt VS Total AssetsBTAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -22.69, we must say that BTAI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -22.69, BTAI is not doing good in the industry: 87.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -22.69
ROIC/WACCN/A
WACC6.78%
BTAI Yearly LT Debt VS Equity VS FCFBTAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 1.87 indicates that BTAI should not have too much problems paying its short term obligations.
BTAI has a Current ratio of 1.87. This is in the lower half of the industry: BTAI underperforms 78.15% of its industry peers.
A Quick Ratio of 1.81 indicates that BTAI should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.81, BTAI is not doing good in the industry: 77.26% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.81
BTAI Yearly Current Assets VS Current LiabilitesBTAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

BTAI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.74%.
BTAI shows a strong growth in Revenue. In the last year, the Revenue has grown by 82.08%.
EPS 1Y (TTM)-37.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.67%
Revenue 1Y (TTM)82.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-37.24%

3.2 Future

Based on estimates for the next years, BTAI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.77% on average per year.
Based on estimates for the next years, BTAI will show a very strong growth in Revenue. The Revenue will grow by 129.15% on average per year.
EPS Next Y-353.72%
EPS Next 2Y-79.68%
EPS Next 3Y-33.54%
EPS Next 5Y14.77%
Revenue Next Year64.77%
Revenue Next 2Y55.59%
Revenue Next 3Y108.04%
Revenue Next 5Y129.15%

3.3 Evolution

BTAI Yearly Revenue VS EstimatesBTAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
BTAI Yearly EPS VS EstimatesBTAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTAI. In the last year negative earnings were reported.
Also next year BTAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTAI Price Earnings VS Forward Price EarningsBTAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTAI Per share dataBTAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

A cheap valuation may be justified as BTAI's earnings are expected to decrease with -33.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-79.68%
EPS Next 3Y-33.54%

More info and screens

0

5. Dividend

5.1 Amount

BTAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOXCEL THERAPEUTICS INC

NASDAQ:BTAI (2/21/2025, 5:08:50 PM)

After market: 2.13 0 (0%)

2.13

-0.17 (-7.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-10 2025-03-10/amc
Inst Owners21.83%
Inst Owner Change171.34%
Ins Owners1.46%
Ins Owner Change1.19%
Market Cap6.43M
Analysts75
Price TargetN/A
Short Float %N/A
Short Ratio1.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)56.54%
Min EPS beat(2)42.08%
Max EPS beat(2)71%
EPS beat(4)3
Avg EPS beat(4)27.27%
Min EPS beat(4)-22.14%
Max EPS beat(4)71%
EPS beat(8)3
Avg EPS beat(8)4.2%
EPS beat(12)5
Avg EPS beat(12)3.2%
EPS beat(16)7
Avg EPS beat(16)2.91%
Revenue beat(2)1
Avg Revenue beat(2)-20.68%
Min Revenue beat(2)-83.93%
Max Revenue beat(2)42.56%
Revenue beat(4)2
Avg Revenue beat(4)-16.64%
Min Revenue beat(4)-83.93%
Max Revenue beat(4)42.56%
Revenue beat(8)2
Avg Revenue beat(8)-32.23%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-45.51%
PT rev (3m)-45.51%
EPS NQ rev (1m)-1206.6%
EPS NQ rev (3m)-985.25%
EPS NY rev (1m)-1403.11%
EPS NY rev (3m)-1250.95%
Revenue NQ rev (1m)-47.08%
Revenue NQ rev (3m)-30.36%
Revenue NY rev (1m)-11.19%
Revenue NY rev (3m)-40.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.83
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.11
EYN/A
EPS(NY)-19.85
Fwd EYN/A
FCF(TTM)-27.84
FCFYN/A
OCF(TTM)-27.84
OCFYN/A
SpS0.75
BVpS-28.36
TBVpS-28.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -145.21%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.98%
FCFM N/A
ROA(3y)-122.7%
ROA(5y)-99.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.87
Quick Ratio 1.81
Altman-Z -22.69
F-Score2
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)66.24%
Cap/Depr(5y)182.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-197.67%
EPS Next Y-353.72%
EPS Next 2Y-79.68%
EPS Next 3Y-33.54%
EPS Next 5Y14.77%
Revenue 1Y (TTM)82.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-37.24%
Revenue Next Year64.77%
Revenue Next 2Y55.59%
Revenue Next 3Y108.04%
Revenue Next 5Y129.15%
EBIT growth 1Y63.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.94%
EBIT Next 3Y16.57%
EBIT Next 5Y14.98%
FCF growth 1Y28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.91%
OCF growth 3YN/A
OCF growth 5YN/A